Role of complement in dengue virus infection: Protection or pathogenesis?

mBio

Volumn 3, Issue 1, 2012, Pages 1-2

  Shresta, Sujan ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD209 ANTIGEN; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C4 BINDING PROTEIN; FC RECEPTOR IIA; MANNOSE BINDING LECTIN; NONSTRUCTURAL PROTEIN 1; TUMOR NECROSIS FACTOR; COMPLEMENT;

ARTICLE; B LYMPHOCYTE; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT SYSTEM; DENGUE; DENGUE VIRUS; DENGUE VIRUS 2; GENE; GENETIC POLYMORPHISM; HUMAN; IMMUNOREGULATION; INFECTION CONTROL; MBL2 GENE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; T LYMPHOCYTE; VIRUS ENTRY; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; VIRUS PATHOGENESIS; ANIMAL; IMMUNOLOGY; NOTE; VIRUS INACTIVATION;

DENGUE VIRUS; DENGUE VIRUS GROUP;

ANIMALS; COMPLEMENT SYSTEM PROTEINS; DENGUE VIRUS; HUMANS; MANNOSE-BINDING LECTIN; VIRUS INACTIVATION;

EID: 84857860198     PISSN: None     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00003-12     Document Type: Article

References (19)

1. Dengue Vaccine Initiative. 2012. Disease burden. http://www.denguevaccines.org/disease-burden.
2. Halstead SB. 1988. Pathogenesis of dengue: challenges to molecular biology. Science 239:476-481.
3. Rothman AL. 2011. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat. Rev. Immunol. 11:532-543.
4. Rico-Hesse R. 2007. Dengue virus evolution and virulence models. Clin. Infect. Dis. 44:1462-1466.
5. Coffey LL, et al. 2009. Human genetic determinants of dengue virus susceptibility. Microbes Infect. 11:143-156.
6. Avirutnan P, et al. 2011. Complement-mediated neutralization of dengue virus requires mannose-binding lectin. mBio 2(6):e00276-11. http://dx.doi.org/10.1128/mBio.00276-11
7. Madsen HO, et al. 1994. A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immu-nogenetics 40:37-44.
8. Bokisch VA, Top FH, Russell PK, Dixon FJ, Müller-Eberhard HJ. 1973. The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N. Engl J. Med. 289:996-1000.
9. Cardosa MJ, Porterfield JS, Gordon S. 1983. Complement receptor mediates enhanced flavivirus replication in macrophages. J. Exp. Med. 158:258-263.
10. Avirutnan P, Malasit P, Seliger B, Bhakdi S, Husmann M. 1998. Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. J. Immunol. 161:6338-6346.
11. Avirutnan P, et al. 2006. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J. Infect. Dis. 193:1078-1088.
12. Nascimento EJ, et al. 2009. Alternative complement pathway deregulation is correlated with dengue severity. PLoS One 4:e6782.
13. Yamanaka A, Kosugi S, Konishi E. 2008. Infection-enhancing and -neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J. Virol. 82: 927-937.
14. Mehlhop E, et al. 2007. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2:417-426.
15. Avirutnan P, et al. 2010. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J. Exp. Med. 207:793-806.
16. Avirutnan P, et al. 2011. Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation. J. Immunol. 187:424-433.
17. Brown KS, Ryder SD, Irving WL, Sim RB, Hickling TP. 2007. Mannan binding lectin and viral hepatitis. Immunol. Lett. 108:34-44.
18. Garred P, et al. 1994. Dual role of mannan-binding protein in infections: another case of heterosis? Eur. J. Immunogenet. 21:125-131.
19. Acioli-Santos B, et al. 2008. MBL2 gene polymorphisms protect against development of thrombocytopenia associated with severe dengue pheno-type. Hum. Immunol. 69:122-128.